D L Carlson Investment Group Inc. lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 8.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 70,366 shares of the biopharmaceutical company’s stock after selling 6,146 shares during the quarter. D L Carlson Investment Group Inc.’s holdings in Bristol-Myers Squibb were worth $4,877,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. True Wealth Design LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $26,000. GoalVest Advisory LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $29,000. Coppell Advisory Solutions Corp. bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $31,000. Live Oak Investment Partners purchased a new position in Bristol-Myers Squibb in the 4th quarter worth $33,000. Finally, First Personal Financial Services lifted its stake in Bristol-Myers Squibb by 67.8% in the first quarter. First Personal Financial Services now owns 495 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 200 shares during the last quarter. 74.98% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
BMY has been the topic of a number of recent research reports. HSBC assumed coverage on Bristol-Myers Squibb in a research note on Friday, July 14th. They set a “reduce” rating and a $56.00 price objective on the stock. Credit Suisse Group decreased their price target on Bristol-Myers Squibb from $72.00 to $66.00 in a research note on Wednesday, July 12th. SVB Securities assumed coverage on Bristol-Myers Squibb in a research note on Monday, July 10th. They set a “market perform” rating and a $66.00 price objective for the company. Bank of America decreased their target price on shares of Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, July 28th. Finally, Daiwa Capital Markets initiated coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, June 28th. They set an “outperform” rating and a $70.00 price target for the company. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $71.14.
Insider Activity at Bristol-Myers Squibb
In other Bristol-Myers Squibb news, EVP Robert M. Plenge sold 732 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total transaction of $44,754.48. Following the completion of the transaction, the executive vice president now owns 6,584 shares of the company’s stock, valued at $402,545.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Robert M. Plenge sold 732 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $61.14, for a total value of $44,754.48. Following the sale, the executive vice president now owns 6,584 shares in the company, valued at approximately $402,545.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ann Powell sold 17,986 shares of Bristol-Myers Squibb stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the transaction, the executive vice president now owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Stock Down 0.9 %
Shares of NYSE:BMY opened at $60.24 on Wednesday. The firm has a market capitalization of $125.85 billion, a P/E ratio of 16.02, a P/E/G ratio of 1.58 and a beta of 0.42. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.28 and a current ratio of 1.39. The stock has a 50 day moving average price of $61.88 and a 200-day moving average price of $65.33. Bristol-Myers Squibb has a 52-week low of $59.45 and a 52-week high of $81.43.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The firm had revenue of $11.23 billion during the quarter, compared to the consensus estimate of $11.81 billion. During the same quarter last year, the company posted $1.93 EPS. Bristol-Myers Squibb’s revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 7.49 EPS for the current fiscal year.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Bristol-Myers Squibb
- Golden Cross Stocks: Pattern, Examples and Charts
- Ray Dalio’s Move into 3 Stocks, All Betting on One Thing
- How to Invest in Artificial Intelligence
- Airbnb Joins the S&P 500, Time to Buy In?
- Investing in the High PE Growth Stocks
- Does Dell Technologies Blowout Quarter Mean a New Demand Cycle?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
